Drugmakers Pfizer and Moderna maybe doing a great service to humanity with an express delivery of COVID-19 vaccines but it will prove to be their biggest cash cow.

According to a CNN report, Wall Street analysts are projecting Pfizer and Moderna will generate $32 billion in COVID-19 vaccine revenue in 2021.

Pfizer is projected to get the lion’s share of $19 billion,with Moderna taking in another $13 billion, not taking into account the goodwill that these companies will generate.

Pfizer will split its revenues with BioNTech, the German company it partnered with to develop the vaccine. 

If true, these estimates are well above any revenue that these companies ever generated in a year. Although Pfizer’s stock has barely risen (12.5% this year),its partner BioNTech is booming. The company’s US-listed shares have skyrocketed nearly 300%, pushing its valuation to nearly $30 billion.

Also read: US expert committee votes in for emergency use of Pfizer’s COVID-19 vaccine

Moderna’s shares have also blown the roof, rising nearly 700% this year and Morgan Stanley estimates that around half of the company’s market value is attached to its COVID-19 vaccine.

It generated just $60 million in sales in 2019 and has never previously licensed a product.

“It’s an historic achievement in drug development. To take a new technology in such a young company and have it ready just in time for the worst pandemic in a century is hard to imagine,” Alan Carr, a biotech analyst, was quoted by CNN as saying.